Almirall notes "good traction in Europe" for psoriasis cream Wynzora

The Spanish skin health firm’s psoriasis business continues to grow in H1, driven in part by the cream dubbed Wynzora, which was developed by MC2 Therapeutics.

Photo: Almirall / PR

Psoriasis cream Wynzora has gotten off to a flying start on the European market, winning 7% and 6% market shares in Germany and Spain, respectively, reports the Spanish dermatology firm that sells the treatment, Almirall, in connection with its H1 report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs